Introduction {#s0005}
============

Vulvar intraepithelial neoplasia (VIN) is a premalignant disease of the squamous epithelium. It is described as a proliferation of abnormal keratinocytes limited to the epidermis without invasion of the basement membrane. Historically, various terms have been used to define cancer precursors of the vulva including VIN grades 1-3 and Bowen's disease. In 2004, the International Society for the Study of Vulvovaginal Disease reclassified VIN to refer only to high-grade intraepithelial lesions of the vulva, including older clinical terms such as *Bowen's disease*, *dysplasia*, and *squamous cell carcinoma in situ* ([@bb0030]).

VIN is classified into two distinct subtypes. Usual type is associated with high-risk oncogenic human papillomavirus (HPV) infection, cigarette smoking, and immunodeficiency. The less common differentiated type typically occurs in postmenopausal women and is associated with chronic dermatoses, including lichen sclerosis, and HPV-negative vulvar cancer. Although VIN is an uncommon disease, incidence is increasing, particularly in women younger than the age of 50 years. The clinical presentation of VIN is diverse, and patients may be asymptomatic or have severe pruritus, pain, burning, and dyspareunia.

Treatment of VIN is indicated to decrease progression to invasive disease along with relieving symptoms. Due to the rare incidence of VIN, there are few large randomized studies, and consequently limited data from which to form guidelines for treatment and follow-up. Surgery, with wide local excision or vulvectomy, is currently the standard of care for the treatment of VIN. It allows examination of tissue margins, which is especially helpful in invasive disease. However, surgery often results in significant morbidity, including sexual and psychosocial dysfunction, and is associated with a high rate of recurrence ([@bb0010]). Alternatively, medical management of VIN has been investigated. Nonsurgical therapy may prevent disfigurement and preserve sexual function, but is limited to patients with no evidence or suspicion of invasive disease on clinical exam or biopsy. Available therapeutic options for conservative treatment of VIN include imiquimod, cidofovir, indole-3-carbinol, photodynamic therapy, and laser ablation ([@bb0005], [@bb0010]).

Imiquimod is an immune response-modifying agent currently FDA approved for the topical treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts. Although a number of studies support the use of topical imiquimod for the conservative treatment of VIN, clear guidelines for optimal treatment duration and follow-up timeline have not yet been determined. We report a case of a woman who was diagnosed with unifocal VIN and treated with 5% topical imiquimod cream with complete response.

Case Report {#s0010}
===========

A 75-year-old woman was referred to our dermatology department for an asymptomatic vulvar lesion of unknown duration. The lesion was histologically classified as HPV-related VIN with full thickness atypia. The patient was interested in pursuing nonsurgical options before resorting to vulvectomy. She denied pruritus, pain, dysuria, and dyspareunia. No prior treatments had been tried.

Physical exam revealed a 5×3 mm white plaque on the right aspect of the clitoral hood ([Fig. 1](#f0005){ref-type="fig"}). Initial biopsy of the lesion demonstrated full-thickness marked atypia, occasional cleared out cytoplasm (haloes), and parakeratosis, most consistent with HPV-related VIN ([Fig. 2](#f0010){ref-type="fig"}).

Treatment was initiated with topical imiquimod 5% cream, five times per week, for 12 weeks. The lesion was re-evaluated after 12 weeks of treatment and repeat biopsy was performed. Subsequent biopsy showed moderate to severe squamous dysplasia confined to the basal cell layer with an intense lichenoid inflammatory reaction ([Fig. 3](#f0015){ref-type="fig"}). No VIN was seen. We repeated an additional course of topical imiquimod 5% cream, five times per week for an additional 12 weeks. Shave biopsy after 24 weeks of imiquimod therapy demonstrated lichenoid dermatitis with no residual dysplasia or carcinoma ([Fig. 4](#f0020){ref-type="fig"}). Side effects included local irritation, pain, and candidal infection during the course of treatment. Treatment was stopped and patient was evaluated at 3, 6, and 9 months without signs and symptoms of recurrence ([Fig. 5](#f0025){ref-type="fig"}).

Discussion {#s0015}
==========

Imiquimod, a heterolytic imidazoquinoline amide, is an effective alternative to surgery for the treatment of VIN. Classified as an immune response-modifying drug, imiquimod enhances local skin immune responses by activating toll-like receptor-7 and -8 on macrophages and dendritic cells, which induces the release of pro-inflammatory T-helper cell type 1 cytokines (interferon-α, interleukin-2, interleukin-12) and upregulates cell-mediated immunity ([@bb0025]). This results in an antiviral and proapoptotic effect on HPV-infected abnormal cells. Side effects include local pruritus, pain, burning, irritation, and soreness, which are generally well tolerated. Patients with biopsy-proven invasive disease are excluded from medical management. Surgical treatment should be considered for lesions that do not respond to medical therapy.

A number of studies support the use of topical imiquimod as the conservative treatment of choice for women with VIN ([Table 1](#t0005){ref-type="table"}). In a review of three clinical trials, the frequency of application of imiquimod 5% cream ranged from two to three times weekly, with some studies employing slow frequency escalation ([@bb0015], [@bb0020], [@bb0040]). The duration of treatment lasted 16 weeks in all studies, and follow up ranged from 2 months to more than 7 years. The results of these studies demonstrated complete response rates ranging from 30 to 81%, partial response from 9.5 to 38%, and no response from 9 to 30%.

Based on a review of the literature, small (\< 1 cm) lesions are more likely to demonstrate a complete response to imiquimod treatment. However, treatment periods in the randomized controlled trials may have been too short to be effective for larger (\> 5 cm) lesions. A significant association was seen between the local skin reaction achieved and complete disease regression. Those that reached a higher degree of local irritation had a better likelihood of observed complete response to treatment ([@bb0015]). Another potential predictive marker of imiquimod response includes viral clearance, as complete histologic regression of lesions strongly correlates with HPV clearance (*p* \< .001) ([@bb0040]). Patients with complete regression also demonstrated a significant increase in the number of immune cells (CD1a + dendritic cells, CD8 + T cells, and CD94 + natural killer cells) in the epidermis with completion of therapy. Total amount of imiquimod used did not correlate with observed response to treatment or recurrence rate ([@bb0015]). Lesion distribution (unifocal vs. multifocal) has not been associated with treatment response (*p* = .66) ([@bb0015]). Imiquimod cream is able to upregulate the immune response, not only in areas with direct contact to the topical, but also in adjacent areas, which is advantageous when skip lesions may be present.

In addition to effects on histologic regression, imiquimod reduces pruritus and pain associated with VIN (*p* = .008 and *p* = .004, respectively) ([@bb0040]). In patients with a partial response to imiquimod, clinically significant decreased lesion size may be seen, leading to surgical resection with better-preserved sexual function and improved cosmetic result.

An additional benefit of imiquimod is the continued immunostimulant effect on the area after treatment, preventing HPV expression and VIN recurrence. [@bb0035] report on the 7-year follow-up of 24 of 26 patients treated with imiquimod in their original study ([@bb0040]). Of the complete responders, eight of nine had no recurrence of VIN. One patient had recurrence of VIN 4 years after demonstrating a complete response to imiquimod. [@bb0015] demonstrated a significantly lower rate of recurrence and longer time to recurrence compared with primary surgically treated patients (*p* = .013). Prognostic variables related to VIN recurrence include age at diagnosis, smoking, and HPV status. A significantly higher recurrence rate is seen in women aged 65 or older compared with that of women younger than age 65 years (*p* = .03) ([@bb0045]). All five patients who had recurrence after complete response to imiquimod in [@bb0015] had a smoking history of at least one pack per day. VIN recurrence rate is also higher in women with initial HPV-negative disease. Despite the immunostimulant effect, follow-up visits to monitor for recurrence and long-term effects should be employed and biopsy of suspicious areas should be performed for all patients.

Women with a history of VIN should be considered at risk for VIN recurrence or vulvar cancer throughout their lifetime. Post-treatment surveillance has been limited in most studies. [@bb0040] performed post-treatment assessments at 7 and 12 months. In women with a complete response to imiquimod therapy, we recommend follow up at 3, 6, and 12 months with annual visits thereafter given the slow rate of progression.

In conjunction with the results of these studies, our experience confirmed topical imiquimod is effective in the treatment of VIN. Imiquimod is effective, convenient, self-administered, and well tolerated. Invasive disease must be ruled out before starting imiquimod therapy. Ideal candidates for imiquimod therapy include nonsmoking, HPV-positive patients younger than age 65 years with small lesions. A longer duration of treatment is needed for patients with larger lesions. Slow dose escalation and frequent clinic visits to provide reassurance resulted in improved tolerability and successful completion of the treatment regimen. A thorough follow-up regimen is recommended to monitor for recurrence and progression to invasive disease.

![5×3 mm white plaque on the right aspect of the clitoral hood during imiquimod therapy.](gr1){#f0005}

![Pretreatment histopathology: Full-thickness involvement of the vulvar mucosa by a proliferation of markedly atypical, hyperchromatic cells with high nuclear-to-cytoplasmic ratio, and irregular nuclear borders. Some cells show cleared out cytoplasm, suggesting human papillomavirus (HPV) effect (H&E, 20 ×).](gr2){#f0010}

![Twelve-week histopathology: Subtotal involvement of the vulvar mucosa by moderate to severe squamous dysplasia. Intense lichenoid inflammatory infiltrate noted in the underlying submucosa (H&E, 20 ×).](gr3){#f0015}

![Twenty-four week histopathology: Vulvar mucosa with mild lichenoid dermatitis. No significant cytologic atypia or dysplasia is present (H&E, 20 ×).](gr4){#f0020}

![Clearance of lesion 12 weeks after completion of treatment.](gr5){#f0025}

###### 

Imiquimod for the Treatment of Vulvar Intraepithelial Neoplasia: Review of the Literature

  Source      No. of patients (T/C)   Treatment method                                                                                                       Pathologic regression                        Mean follow up (mo)   No. of recurrences (CR/C)   Progression to invasive disease (CR/C)                                                     
  ----------- ----------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------- --------------------------- ---------------------------------------- ------------------------------------------------- -----
  [@bb0020]   21/10                   16 weeks: qWeek for 2 weeks, BIW following 2 weeks, TIW last 12 weeks. Biopsy taken 2 months after end of treatment.   17 (81)/0[⁎](#tf0005){ref-type="table-fn"}   2 (9.5)/0             2 (9.5)/0                   2                                        NM                                                0/0
  [@bb0015]   33                      16 weeks: qWeek for 2 weeks, BIW following 2 weeks, TIW last 12 weeks. Biopsy taken at end of 16 week treatment.       21 (64)/NM                                   9 (27)/NM             3 (9)/NM                    16                                       5 (24)/NM (54)[†](#tf0010){ref-type="table-fn"}   0
  [@bb0040]   26/26                   16 weeks: BIW for 16 weeks. Biopsy taken at end of 20 weeks                                                            8 (30)/0                                     10 (38)/(4)           8 (30)/25(96)               12                                       0/NM                                              0/2
  [@bb0035]   24/-                    Long-term follow-up of CR in van Seters et al. for at least 5 years                                                    \-                                           \-                    \-                          86                                       1 (11)                                            0

BIW, twice per week; CR, complete response; NM, not mentioned; NR, no response; PR, partial response; qWeek, once per weekly; T/C, treatment group/control group; TIW, three times per week

*p* \< .001.

*p* = .013.
